{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.05","upperLimit":"0.85","value":"0.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The proportion of successful stem cell collection following initial therapy with the combination of pembrolizumab, lenalidomide and dexamethasone in patients with newly diagnosed MM will be estimated by the number of patients with a successful stem cell collection divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true successful proportion will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg lenalidomide PO daily on days 1-21 and 40 mg dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive 200 mg pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.","id":"OG000","title":"Treatment (Lenalidomide, Dexamethasone, Pembrolizumab)"}],"paramType":"NUMBER","populationDescription":"Only patients that completed 4 cycles of treatment were eligible for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 112 days","title":"Proportion of Successful Stem Cell Collection","type":"SECONDARY","unitOfMeasure":"proportion of participants"}